Silvia Betti

Rome, Italy

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 50 publications

Impact of cytoreductive therapy in myeloproliferative neoplasm-associated splanchnic vein thrombosis.

Impact of cytoreductive therapy in myeloproliferative neoplasm-associated splanchnic vein thrombosis.

Journal: Blood advances

Published: May 18, 2026

TP53 Mutations Unfavorably Impact the Outcomes of Myelofibrosis Patients with or Without Hematopoietic Stem Cell Transplantation: A Single-Center Study and Meta-Analysis.

TP53 Mutations Unfavorably Impact the Outcomes of Myelofibrosis Patients with or Without Hematopoietic Stem Cell Transplantation: A Single-Center Study and Meta-Analysis.

Journal: International journal of molecular sciences

Published: April 21, 2026

High Frequency of Germline ATM Variants in Familial Philadelphia-Negative Myeloproliferative Neoplasms.

High Frequency of Germline ATM Variants in Familial Philadelphia-Negative Myeloproliferative Neoplasms.

Journal: American journal of hematology

Published: November 11, 2025

The influence of patient engagement and self-efficacy on self-care in myeloproliferative neoplasms: A mediation analysis.

The influence of patient engagement and self-efficacy on self-care in myeloproliferative neoplasms: A mediation analysis.

Journal: European journal of oncology nursing : the official journal of European Oncology Nursing Society

Published: October 29, 2025

Metabolic profiling of therapy-induced senescent cancer cells via TPEF, MALDI-MS, and RNA-sequencing.

Metabolic profiling of therapy-induced senescent cancer cells via TPEF, MALDI-MS, and RNA-sequencing.

Journal: Scientific reports

Published: September 10, 2025

Exploring thromboembolic risk factors in polycythemia vera: from current evidence to PROSPERO study design.

Exploring thromboembolic risk factors in polycythemia vera: from current evidence to PROSPERO study design.

Journal: Annals of hematology

Published: March 25, 2025

Improving the management of Polycythemia Vera patients eligible for cytoreduction: report of a multidisciplinary advisory board.

Improving the management of Polycythemia Vera patients eligible for cytoreduction: report of a multidisciplinary advisory board.

Journal: Current medical research and opinion

Published: January 30, 2025

Long-term pharmacodynamic and clinical effects of twice- versus once-daily low-dose aspirin in essential thrombocythemia: The ARES trial.

Long-term pharmacodynamic and clinical effects of twice- versus once-daily low-dose aspirin in essential thrombocythemia: The ARES trial.

Journal: American journal of hematology

Published: April 11, 2024

Ropeginterferon versus Standard Therapy for Low-Risk Patients with Polycythemia Vera.

Ropeginterferon versus Standard Therapy for Low-Risk Patients with Polycythemia Vera.

Journal: NEJM evidence

Published: February 06, 2024

Ropeginterferon phase 2 randomized study in low-risk polycythemia vera: 5-year drug survival and efficacy outcomes.

Ropeginterferon phase 2 randomized study in low-risk polycythemia vera: 5-year drug survival and efficacy outcomes.

Journal: Annals of hematology

Published: November 13, 2023

Breakthrough infections in MPN-COVID vaccinated patients.

Breakthrough infections in MPN-COVID vaccinated patients.

Journal: Blood cancer journal

Published: October 19, 2022

Assessment of the efficacy and tolerability of ruxolitinib for the treatment of myelofibrosis patients in a real-life setting: An Italian MYNERVA Project.

Assessment of the efficacy and tolerability of ruxolitinib for the treatment of myelofibrosis patients in a real-life setting: An Italian MYNERVA Project.

Journal: Cancer medicine

Published: October 17, 2022

Showing 1-12 of 50

Last Updated: 09/26/2026